|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
19
|
|
pubmed:dateCreated |
2006-9-14
|
|
pubmed:abstractText |
The fumagillin family of natural products inhibits angiogenesis through the irreversible inhibition of the type 2 methionine aminopeptidase (MetAP2). Herein is reported a novel fumagillin analogue named fumarranol. It is shown that, like fumagillin, fumarranol selectively inhibits MetAP2 and endothelial cell proliferation. It is also active in a mouse model of angiogenesis in vivo. Unlike TNP-470, fumarranol does not covalently bind to MetAP2. Fumarranol may serve as a lead for a new class of angiogenesis inhibitors.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Aminopeptidases,
http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Collagen,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclohexanes,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Fatty Acids, Unsaturated,
http://linkedlifedata.com/resource/pubmed/chemical/Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Laminin,
http://linkedlifedata.com/resource/pubmed/chemical/METAP2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Proteoglycans,
http://linkedlifedata.com/resource/pubmed/chemical/Sesquiterpenes,
http://linkedlifedata.com/resource/pubmed/chemical/fumagillin,
http://linkedlifedata.com/resource/pubmed/chemical/matrigel
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0022-2623
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
21
|
|
pubmed:volume |
49
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5645-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16970390-Aminopeptidases,
pubmed-meshheading:16970390-Angiogenesis Inhibitors,
pubmed-meshheading:16970390-Animals,
pubmed-meshheading:16970390-Cattle,
pubmed-meshheading:16970390-Cell Proliferation,
pubmed-meshheading:16970390-Cells, Cultured,
pubmed-meshheading:16970390-Collagen,
pubmed-meshheading:16970390-Crystallography, X-Ray,
pubmed-meshheading:16970390-Cyclohexanes,
pubmed-meshheading:16970390-Drug Combinations,
pubmed-meshheading:16970390-Endothelial Cells,
pubmed-meshheading:16970390-Endothelium, Vascular,
pubmed-meshheading:16970390-Fatty Acids, Unsaturated,
pubmed-meshheading:16970390-Glycoproteins,
pubmed-meshheading:16970390-Laminin,
pubmed-meshheading:16970390-Mice,
pubmed-meshheading:16970390-Molecular Structure,
pubmed-meshheading:16970390-Proteoglycans,
pubmed-meshheading:16970390-Sesquiterpenes,
pubmed-meshheading:16970390-Structure-Activity Relationship
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Fumarranol, a rearranged fumagillin analogue that inhibits angiogenesis in vivo.
|
|
pubmed:affiliation |
Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
